Clinical Pharmacology and Therapeutics - Table of Contents alert Volume 91 Issue 1

TABLE OF CONTENTS Volume 91, Issue 1 (January 2012) In this issue In This Issue Editorial News & Views Perspectives Reviews Corrigendum Also new AOP Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement A personalized experience in clinical trial publishing. Network with Pharma Solutions on Linked In. Our group connects key decision makers in clinical trial publishing, including lead investigators, pharmaceutical companies, and medical communication agencies. Join in discussions and hot topics shaping the industry.   In This Issue Top IN THIS ISSUE Clin Pharmacol Ther 2012 91: 1; 10.1038/clpt.2011.315 Full Text Editorial Top EDITORIAL Knowledge Cycle Transforms Therapeutic Innovation S A Waldman and A Terzic Clin Pharmacol Ther 2012 91: 3-8; 10.1038/clpt.2011.299 Full Text News & Views Top HIGHLIGHTS Clin Pharmacol Ther 2012 91: 10-11; 10.1038/clpt.2011.314 Full Text ASCPT NEWS Clin Pharmacol Ther 2012 91: 12-14; 10.1038/clpt.2011.291 Full Text Perspectives Top COMMENTARIES Therapeutic Additions and Possible Deletions in Oncology in 2011 S A Holstein and R J Hohl Clin Pharmacol Ther 2012 91: 15-17; 10.1038/clpt.2011.288 Abstract | Full Text Innovation in Biotechnology: Current and Future States G R Woollett Clin Pharmacol Ther 2012 91: 17-20; 10.1038/clpt.2011.219 Abstract | Full Text Reviews Top REVIEW Stem Cell Senescence and Regenerative Paradigms A P Beltrami, D Cesselli and C A Beltrami Clin Pharmacol Ther 2012 91: 21-29; advance online publication, November 16, 2011; 10.1038/clpt.2011.262 Abstract | Full Text Biologics-Based Therapy for the Treatment of Rheumatoid Arthritis D L Scott Clin Pharmacol Ther 2012 91: 30-43; advance online publication, December 14, 2011; 10.1038/clpt.2011.278 Abstract | Full Text Pharmacology of the New Treatments for Lower Gastrointestinal Motility Disorders and Irritable Bowel Syndrome M Camilleri Clin Pharmacol Ther 2012 91: 44-59; advance online publication, November 9, 2011; 10.1038/clpt.2011.261 Full Text Vaccines Against Drug Abuse X Y Shen, F M Orson and T R Kosten Clin Pharmacol Ther 2012 91: 60-70; advance online publication, November 30, 2011; 10.1038/clpt.2011.281 Abstract | Full Text Vandetanib for the Treatment of Thyroid Cancer P B Langmuir and A Yver Clin Pharmacol Ther 2012 91: 71-80; advance online publication, December 7, 2011; 10.1038/clpt.2011.272 Abstract | Full Text Tissue-Engineered Airway: A Regenerative Solution P Jungebluth, G Moll, S Baiguera and P Macchiarini Clin Pharmacol Ther 2012 91: 81-93; advance online publication, November 30, 2011; 10.1038/clpt.2011.270 Abstract | Full Text State-of-the-Art Implantable Cardiac Assist Device Therapy for Heart Failure: Bridge to Transplant and Destination Therapy S J Park, S S Kushwaha and C G A McGregor Clin Pharmacol Ther 2012 91: 94-100; advance online publication, November 23, 2011; 10.1038/clpt.2011.274 Abstract | Full Text Development and Clinical Utility of Abiraterone Acetate as an Androgen Synthesis Inhibitor A Bryce and C J Ryan Clin Pharmacol Ther 2012 91: 101-108; advance online publication, November 30, 2011; 10.1038/clpt.2011.275 Abstract | Full Text Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction D E Gutstein, R Krishna, D Johns, H K Surks, H M Dansky, S Shah, Y B Mitchel, J Arena and J A Wagner Clin Pharmacol Ther 2012 91: 109-122; advance online publication, November 30, 2011; 10.1038/clpt.2011.271 Abstract | Full Text Denosumab for the Treatment of Osteoporosis and Cancer-Related Conditions E M Lewiecki and J P Bilezikian Clin Pharmacol Ther 2012 91: 123-133; advance online publication, December 7, 2011; 10.1038/clpt.2011.268 Abstract | Full Text PDE4: A Novel Target in the Treatment of Chronic Obstructive Pulmonary Disease J M Michalski, G Golden, J Ikari and S I Rennard Clin Pharmacol Ther 2012 91: 134-142; advance online publication, November 30, 2011; 10.1038/clpt.2011.266 Abstract | Full Text Belimumab: A BLyS-Specific Inhibitor for the Treatment of Systemic Lupus Erythematosus G J Dennis Clin Pharmacol Ther 2012 91: 143-149; advance online publication, November 30, 2011; 10.1038/clpt.2011.290 Abstract | Full Text Corrigendum Top CORRIGENDUM CORRIGENDUM: Refining the Benefit–Risk Framework for the Assessment of Medicines: Valuing and Weighting Benefit and Risk Parameters Clin Pharmacol Ther 2012 91: 150; 10.1038/clpt.2011.259 Full Text Advertisement Ensure your access If you are unable to access the articles in thisalert, your library may not subscribe to this journal. Our online recommendation form is a simple way to make your librarian aware that this journal is valuable to your research. Recommend now at http://www.nature.com/librec/svc/request/makeProdRequest?id=clpt   Please note that you need to be a subscriber or site-license holder to enjoy full-text access to Clinical Pharmacology & Therapeutics. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2011 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.